Nanjing Jiangbei New Area and Singleron Mutually Built Sing-cell Public Sercive Platform

Jan 11,2021

On Jan 11, Nanjing Jiangbei New Area Biopharmaceutical Public Service Platform and Singleron Biotech signed a co-construction agreement for Jiangbei New Area Single Cell Public Service Platform. Chen Chanmei, Deputy Director of Nanjing Jiangbei New Area Administration Committe, and Fang Nan, CEO of Singleron Biotech attended the event. At the same time, a single-cell sequencing technology and application salon was held.

Jiangbei New Area Single-cell Public Service Platform was mutually built by Nanjing Jiangbei New Area Biopharmaceutical Public Service Platform and Singleron Biotechtech by integrating Jiangbei New Area single-cell R&D application technology and the platform's resources. The platform will create independent intellectual property rights by combining Jiangbei New Area Biopharmaceutical Public Service Platform's strong sequencing capacity to form a complete single-cell sequencing chain and a one-stop solution from sample processing transport processing to bio-info analysis. This platform is based in Nanjing, covering the entire eastern China region and radiation throughout the country. It will provide single-cell sequencing service for the vast number of universities, hospitals, research institutes, pharmaceutical enterprises, science and technology services enterprises.